Patents by Inventor Jacques F. Banchereau

Jacques F. Banchereau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fusion proteins comprising an anti-CD40 antibody and cancer antigens
    Patent number: 11806390
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: November 7, 2023
    Assignee: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • Compositions and Methods for the Systemic Treatment of Arthritis
    Publication number: 20230134568
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Application
    Filed: August 8, 2022
    Publication date: May 4, 2023
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual
  • ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20220340670
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: March 7, 2022
    Publication date: October 27, 2022
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Compositions and methods for the systemic treatment of arthritis
    Patent number: 11406688
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: August 9, 2022
    Assignee: BAYLOR RESEARCH INSTITUTE
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual
  • Nucleic acids encoding anti-CD40 antibodies
    Patent number: 11267895
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: June 15, 2020
    Date of Patent: March 8, 2022
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • FUSION PROTEINS COMPRISING AN ANTI-CD40 ANTIBODY AND CANCER ANTIGENS
    Publication number: 20210308242
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: April 12, 2021
    Publication date: October 7, 2021
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard ZURAWSKI, Jacques F. Banchereau, Anne-Laure FLAMAR, Peter KLUCAR, Keiko AKAGAWA, Sandra ZURAWSKI, SangKon OH
  • FUSION PROTEINS COMPRISING AN ANTI-CD40 ANTIBODY AND HIV ANTIGENIC PEPTIDES
    Publication number: 20210221904
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: March 25, 2021
    Publication date: July 22, 2021
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Gerard ZURAWSKI, Jacques F. Banchereau, Anne-Laure FLAMAR, Yves Levy, Monica Montes
  • Fusion proteins comprising an anti-CD40 antibody and HIV antigenic peptides
    Patent number: 10988544
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: April 27, 2021
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • Fusion proteins comprising an anti-CD40 antibody and cancer antigens
    Patent number: 10980869
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 20, 2021
    Assignee: Baylor Research Institute
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon Oh
  • ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20210024641
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: June 15, 2020
    Publication date: January 28, 2021
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Compositions and Methods for the Systemic Treatment of Arthritis
    Publication number: 20200345813
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Application
    Filed: July 20, 2020
    Publication date: November 5, 2020
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual
  • Compositions and methods for the systemic treatment of arthritis
    Patent number: 10716832
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Grant
    Filed: April 17, 2017
    Date of Patent: July 21, 2020
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual
  • Anti-CD40 antibodies
    Patent number: 10683361
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: September 27, 2018
    Date of Patent: June 16, 2020
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • ANTI-CD40 ANTIBODIES AND USES THEREOF
    Publication number: 20190085088
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: September 27, 2018
    Publication date: March 21, 2019
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Method of making an anti-CD40 antibody
    Patent number: 10087256
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccine and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: October 2, 2018
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Sandra Zurawski, SangKon Oh
  • Methods and compositions for treating breast cancer with dendritic cell vaccines
    Patent number: 10023841
    Abstract: Disclosed are compositions and methods for treatment of breast cancer. Disclosed methods and compositions include dendritic cells loaded with cyclin B1 and WT-1 peptide antigens for immunotherapy. These dendritic cell vaccines are administered alone or in combination with other cancer therapies to improve outcomes. Disclosed methods also involve the use of therapeutic agents, such as anakinra, that block the IL-1 inflammation pathway. These agents are used in combination with chemotherapy and/or immunotherapy in treating breast cancer.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: July 17, 2018
    Assignee: Baylor Research Institute
    Inventors: Anna Karolina Palucka, Jacques F Banchereau, Lee Roberts
  • ANTIGEN PRESENTING CELL TARGETED VACCINES
    Publication number: 20180094071
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: October 18, 2017
    Publication date: April 5, 2018
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Yves Levy, Monica Montes
  • Dendritic cell vaccines
    Patent number: 9862927
    Abstract: Compositions and methods for the prophylaxis and treatment of human immunodeficiency virus (HIV) infections are disclosed herein. More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-?), loading the DC with a mixture of five lipopeptides of Gag, Nef and Pol HIV antigens, and, optionally activating the DC with lipopolysaccharide (LPS).
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: January 9, 2018
    Assignees: Baylor Research Institute, Agence Nationale de Recherches Sur le Sida Et Les Hepatitis Virales
    Inventors: Jacques F. Banchereau, Monica Montes, Anna Karolina Palucka, Louis M. Sloan, Yves Levy
  • ANTIGEN PRESENTING CELL TARGETED CANCER VACCINES
    Publication number: 20180000916
    Abstract: The present invention includes compositions and methods for the expression, secretion and use of novel compositions for use as, e.g., vaccines and antigen delivery vectors, to delivery antigens to antigen presenting cells. In one embodiment, the vector is an anti-CD40 antibody, or fragments thereof, and one or more antigenic peptides linked to the anti-CD40 antibody or fragments thereof, including humanized antibodies.
    Type: Application
    Filed: September 13, 2017
    Publication date: January 4, 2018
    Inventors: Gerard Zurawski, Jacques F. Banchereau, Anne-Laure Flamar, Peter Klucar, Keiko Akagawa, Sandra Zurawski, SangKon OH
  • Compositions and Methods for the Systemic Treatment of Arthritis
    Publication number: 20170281730
    Abstract: The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1?.
    Type: Application
    Filed: April 17, 2017
    Publication date: October 5, 2017
    Inventors: Jacques F. Banchereau, Maria Virginia Pascual